Dr. James Greelish, MD

Cardiac Surgery  ·  
Male  ·  
Age 54
(4)
Insurances Accepted  ·  Save
Dr. James Greelish, MD
Dr. James Greelish, MD is a cardiac surgery specialist in Gastonia, NC and has been practicing for 18 years. He graduated from Wake Forest University in 1992 and specializes in cardiac surgery and cardiothoracic surgery.

Risks associated with the TAVR procedure include death, stroke and major bleeding

Important Risk Information for Patients

Indications:

The Edwards SAPIEN 3 transcatheter heart valve, model 9600TFX, and accessories are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a Heart Team, including a cardiac surgeon, to be at intermediate or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 3% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).

The Edwards SAPIEN 3 transcatheter heart valve, model 9600TFX, and accessories are indicated for patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic or mitral valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 8% at 30 days, based on the STS risk score and other clinical co-morbidities unmeasured by the STS risk calculator).

Contraindications (Who should not use):

The Edwards SAPIEN 3 transcatheter heart valve and delivery system should not be used in patients who:

  • Cannot tolerate medications that thin the blood or prevent blood clots from forming.
  • Have an active infection in the heart or elsewhere.

Warnings:

  • There may be an increased risk of stroke in transcatheter aortic valve replacement procedures, compared to other standard treatments for aortic stenosis in the high or greater risk population.
  • If an incorrect valve size for your anatomy is used, it may lead to heart injury, valve leakage, movement, or dislodgement.
  • Patients should talk to their doctor if they have significant heart disease, a mitral valve device or are allergic to chromium, nickel, molybdenum, manganese, copper, silicon, and/or polymeric materials.
  • The SAPIEN 3 valve may not last as long in patients whose bodies do not process calcium normally.
  • During the procedure, your doctors should monitor the dye used in the body; if used in excess it could lead to kidney damage. X-ray guidance used during the procedure may cause injury to the skin, which may be painful, damaging, and long-lasting.
  • Transcatheter aortic heart valve patients should take medications that thin the blood or prevent blood clots from forming, except when likely to have an adverse reaction, as determined by their physician. The Edwards SAPIEN 3 transcatheter heart valve has not been tested for use without medications that thin the blood or prevent blood clots from forming.

Precautions:

The long-term durability of the Edwards SAPIEN 3 transcatheter heart valve is not known at this time. Regular medical follow-up is recommended to evaluate how well a patient’s heart valve is performing. Safety, performance, and durability of the SAPIEN 3 valve has not been established for placement inside a previously implanted transcatheter valve.

The safety and effectiveness of the transcatheter heart valve is also not known for patients who have:

  • An aortic heart valve that is not calcified, contains only one or two leaflets, has leaflets with large pieces of calcium that may block the vessels that supply blood to the heart or in which the main problem is that the valve leaks.
  • Previous prosthetic ring in any position.
  • Previous atrial septal occlude.
  • A heart that does not pump well, has thickening of the heart muscle, with or without blockage, unusual ultrasound images of the heart that could represent irregularities such as a blood clot, a diseased mitral valve that is calcified or leaking, or Gorlin syndrome, a condition that affects many areas of the body and increases the risk of developing various cancers and tumors.
  • Low white, red or platelet blood cell counts, or history of bleeding because the blood does not clot properly.
  • Diseased, abnormal or irregularly shaped vessels leading to the heart. Vessels which are heavily diseased or too small for associated delivery devices, or a large amount of calcification at the point of entry.
  • Allergies to blood-thinning medications or dye injected during the procedure.
  • For a valve in valve procedure, there is a risk of leakage if the previously implanted tissue valve is not securely in place or if it is damaged. There is also the possibility that a partially detached valve leaflet from the previously implanted valve could block a blood vessel.
  • Additional pre-procedure imaging will be completed to evaluate proper sizing.

Potential risks associated with the procedure include:

  • Death, stroke, paralysis (loss of muscle function), permanent disability, or severe bleeding.
  • Risks to the heart, including heart attack or heart failure, a heart that does not pump well, irregular heartbeat that may result in a need for a permanent pacemaker, chest pain, heart murmur, false aneurysm, recurring aortic stenosis(narrowing), too much fluid around the heart, injury to the structure of the heart.
  • Risks to your lungs or breathing, including difficulty breathing, fainting, buildup of fluid in or around the lungs, weakness or inability to exercise.
  • Risks involving bleeding or your blood supply, including formation of a blood clot, high or low blood pressure, limited blood supply, a decrease in red blood cells, or abnormal lab values, bleeding in the abdominal cavity, collection of blood under the skin.
  • Additional risks, including life-threatening infection, dislodgement of calcified material, air embolism (air bubbles in the blood vessels), poor kidney function or failure, nerve injury, fever, allergic reaction to anesthesia or dye, reoperation, pain, infection or bleeding at incision sites, or swelling.

Additional potential risks specifically associated with the use of the heart valve include:

  • Valve movement after deployment, blockage or disruption of blood flow through the heart, need for additional heart surgery and possible removal of the SAPIEN 3 valve, a blood clot that requires treatment, damage to the valve (e.g., wear, breakage, recurring aortic stenosis), nonstructural valve dysfunction (e.g., leakage, inappropriate sizing or positioning, blockage, excess tissue in growth, blood cell damage, etc.) or mechanical failure of the delivery system and/or accessories.

CAUTION: Federal (United States) law restricts these devices to sale by or on the order of a physician.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, SAPIEN, and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2017 Edwards Lifesciences Corporation. All rights reserved. PP--US-2507 v1.0

Edwards Lifesciences One Edwards Way, Irvine CA 92614 USA edwards.com

2555 Court Dr Ste 200

Gastonia, NC 28054

Contact Information

(704) 671-7670

Dr. James Greelish, MD

Dr. James Greelish, MD

Accepted insurance

  • Accepts most major Health Plans. Please contact our office for details.
  • Aetna
  • Blue Cross Blue Shield
  • Cigna
  • Coventry Health Care
  • Humana
  • MultiPlan
  • UnitedHealthCare

*Please verify this information when scheduling an appointment.

Background Check

No malpractice claims found for North Carolina
No disciplinary actions found for the years we collect data
No board actions found for the years we collect data
Learn more about background checks

Experience Check

Check Dr. Greelish's experience treating your condition or procedure

Dr. Greelish's Top Procedures and Conditions

Treatment Frequency
Port Placements or Replacements
normal
normal

Treatment Frequency

Dr. Greelish performs Port Placements or Replacements more than 81% of his peers

Dr. Greelish performs this procedure more than 81% of his peers

Rating Includes other areas of care:

  • Port Removal
Coronary Artery Disease (CAD)
normal
normal

Treatment Frequency

Dr. Greelish treats Coronary Artery Disease (CAD) more than 72% of his peers

Dr. Greelish treats this condition more than 72% of his peers

Rating Includes other areas of care:

  • Coronary Artery Calcification
  • Coronary Artery Disease, Autosomal Dominant 1
  • Coronary Artery Disease, Autosomal Dominant 2
Pulmonary Disease
normal
normal

Treatment Frequency

Dr. Greelish treats Pulmonary Disease more than 70% of his peers

Dr. Greelish treats this condition more than 70% of his peers

About Me

Care Philosophy

Mutidisciplinary team assessment of patients to arrive at the best patient care decisions. Secondary Specialties: General Surgery

Specialties

  • Cardiac Surgery
  • Cardiothoracic Surgery

Board Certifications

  • General Surgery
  • Thoracic Cardiovascular Surgery
  • Thoracic Surgery

Education

  • 2002
    Harvard Medical School (Brigham and Women's Hospital)
    Residency Hospital
    2002
  • 2000
    Harvard Medical School (Brigham and Women's Hospital)
    Fellowship Hospital
    2000
  • 1999
    The University Of Pennsylvania
    Residency Hospital
    1999
  • 1993
    The University Of Pennsylvania
    Internship Hospital
    1993
  • 1992
    Wake Forest University
    Medical School
    1992

Awards

  • Healthgrades Honor Roll
  • Alpha Omega Alpha, 1992
  • cum laude - Wake Forest Medical School, 1992
  • Jonathan E. Rhoads Research Award, 1998
  • National Research Service Award (NRSA), 1996

Media & Publications

  • Interrelationship between atrial natriuretic factor concentrations and acute volume expansion in pregnant and nonpregnant women. Hatjis CG, Kofinas AD, Greelish JP, Swain M, Rose JC, 1990
  • Greelish, JP, Eagle SS, Zhao, DX, Deegan RJ, Crenshaw MH, Balaguer JM, Ahmad RM, Byrne JG. Management of new-onset mitral regurgitation with intraoperative angiography and intraoperative percutaneous coronary intervention. J Thorac Cardiovasc Surg 2006 Jan;131(1):239-240.,
  • Greelish JP, Su LT, Lankford EB, Stedman HH. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nature Medicine 1999;Apr;5(4):439-443,
  • Greelish JP, Friedberg JS: Secondary pulmonary malignancy. Surgical Clinics of North America 2000; Apr;80(2); 633-657.,
  • Hatjis CG, Kofinas, Greelish JP, Swain M, Rose JC: Atrial natriuretic factor concentrations during pregnancy and in the postpartum period. A J Perinatology 1992;Jul;9(4):275-278., 1992
  • 4. Haecker SE, Stedman HH, Balice-Gordon RJ, Smith DB, Greelish JP, Mitchell MA, Wells A, Sweeney HL, Wilson JM: In vivo expression of full length human dystrophin from adenoviral vectors deleted of all viral genes. Human Gene Therapy 1996;Oct1;7(15):1907-1914.,
  • Neely CF, DiPierro FV, Kong M, Greelish JP, Gardner TJ. A1 adenosine receptor antagonists block ischemia-reperfusion injury of the heart. Circulation, 1996;Nov1;94 (supp 9):II376-380.,
  • Greelish, JP, Ailiwadi M, Balaguer JM, Ahmad RM, Zhao DX, Petracek MR, Byrne JG. Combined percutaneous coronary intervention and valve surgery. Curr Opin Cardiol 2006 Mar;21(2):113-117.,
  • Pretorius M, Donahue BS, Yu C, Greelish JP, Roden DM, Brown NJ. Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation 2007 Sept 11;116(11 Suppl):I1-7.,
  • Greelish JP, Cohn LH, Leacche M, Mitchell M, Karavas A, Fox J, Byrne JG, Aranki SF, Couper GS. Minimally invasive mitral valve repair suggests earlier operations for mitral valve disease. Journal of Thoracic & Cardiovascular Surgery 2003;Aug;126(2):365-371,

Dr. Greelish's Reviews

Likelihood to recommend Dr. Greelish

4.0

Based on 4 reviews

5 Stars
75%
(3)
4 Stars
0%
(0)
3 Stars
0%
(0)
2 Stars
0%
(0)
1 Star
25%
(1)

Leave a review

How likely are you to recommend
Dr. Greelish?
(Select your rating)
Average Wait Time
  • Under 10 minutes
Dr. Greelish's Performance
  • Trustworthiness
  • Explains condition(s) well
  • Answers questions
  • Time well spent
Office & Staff Performance
  • Scheduling
  • Office environment
  • Staff friendliness
What People Say About Dr. James Greelish, MD
Reply
Very inconsiderate toward family of the patient. Complained that he had to cancel his plans because he was operating on my mother's heart. She died.
Was this helpful?
thumbs up icon option4
thumbs down icon option5
×Post a ResponseAre you Dr. James Greelish, MD?

Leave a review

How was your experience with Dr. Greelish?

Locations

Insurance accepted

Accepted insurance can change. Please double-check when making an appointment.

Accepts most major Health Plans. Please contact our office for details.
Aetna
Choice Plus POS II
Blue Cross Blue Shield
Blue Card PPO
Cigna
Cigna HMO
Cigna PPO
Great West Healthcare-Cigna PPO
Open Access
Coventry Health Care
Humana
Choice Care PPO
MultiPlan
MultiPlan PPO
PHCS Network PPO
UnitedHealthCare
Choice Plus POS
Options PPO

Affiliated Hospitals

Check the quality of care at hospitals where Dr. Greelish treats patients.

Learn more

CaroMont Health

Gastonia, NC

Compare Cardiac Surgeons

More providers who are similar to Dr. Greelish

Show All Cardiac Surgeons